241. 高チロシン血症1型
［臨床試験数：14，薬物数：7（DrugBank：1），標的遺伝子数：1，標的パスウェイ数：5］
Searched query = "Hypertyrosinemia type I", "Tyrosinemia type I", "Tyrosinemia I", "Hereditary tyrosinemia, Type I", "Fumarylacetoacetate hydrolase deficiency", "FAH deficiency"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02750709 (ClinicalTrials.gov) | October 2015 | 20/4/2016 | Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin | A Single Center, Single-Dose, Open-Label, Laboratory-Blind, Randomized, Three-Period Crossover Study to Determine the Bioequivalence of Two Oral Formulations Containing of Nitisinone 10 mg Compared to the Reference Formulation Orfadin 10 mg in at Least 18 Healthy Male and Female Subjects Under Fasting Conditions | Hereditary Tyrosinemia, Type I | Drug: Nitisinone;Drug: Nitisinone 10 mg Tablet High Compritol;Drug: Orfadin | Cycle Pharmaceuticals Ltd. | Parexel | Completed | 18 Years | 55 Years | All | 24 | Phase 1 | South Africa |